Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 2
2011 3
2012 1
2013 10
2014 9
2015 11
2016 8
2017 14
2018 16
2019 17
2020 21
2021 17
2022 8
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 35093904

115 results
Results by year
Filters applied: . Clear all
Page 1
Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" study).
Alexopoulos A, Karanikiotis C, Ardavanis A, Boukovinas I, Makrantonakis P, Papadimitriou C, Athanasiadis A, Boutis A, Giassas S, Kakolyris S, Koumakis G, Papazisis K, Psyrri A, Ziras N, Baka S, Kentepozidis N, Michalaki V. Alexopoulos A, et al. Anticancer Res. 2022 Feb;42(2):1031-1041. doi: 10.21873/anticanres.15564. Anticancer Res. 2022. PMID: 35093904
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P. Jerusalem G, et al. Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358383 Free article. Clinical Trial.
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. Pritchard KI, et al. Clin Breast Cancer. 2013 Dec;13(6):421-432.e8. doi: 10.1016/j.clbc.2013.08.011. Clin Breast Cancer. 2013. PMID: 24267730 Free article. Clinical Trial.
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. Campone M, et al. Eur J Cancer. 2013 Aug;49(12):2621-32. doi: 10.1016/j.ejca.2013.04.011. Epub 2013 Jun 1. Eur J Cancer. 2013. PMID: 23735704 Free article.
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA. Tesch H, et al. Int J Cancer. 2019 Feb 15;144(4):877-885. doi: 10.1002/ijc.31738. Epub 2018 Oct 30. Int J Cancer. 2019. PMID: 29992557 Free PMC article. Clinical Trial.
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, Ficorella C, Frassoldati A, Fumagalli A, Garrone O, Gebbia V, Generali D, La Verde N, Maur M, Michelotti A, Moretti G, Musolino A, Palumbo R, Pistelli M, Porpiglia M, Sartori D, Scavelli C, Schirone A, Turletti A, Valerio MR, Vici P, Zambelli A, Clivio L, Torri V; on behalf of; EVA Study Group. Cazzaniga ME, et al. Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13. Breast. 2017. PMID: 28711793
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S. Bilici A, et al. Cancer Invest. 2022 Feb;40(2):199-209. doi: 10.1080/07357907.2021.2017952. Epub 2021 Dec 22. Cancer Invest. 2022. PMID: 34894960
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Im YH, Karabulut B, Lee KS, Park BW, Adhav A, Cinkir HY, Abdel-Razeq H, Chang YC, Aksoy S, Im SA, Jeong J, Chae Y, Bowles J, Slimane K, Xue H, Kim SB. Im YH, et al. Breast Cancer Res Treat. 2021 Jul;188(1):77-89. doi: 10.1007/s10549-021-06173-z. Epub 2021 Mar 16. Breast Cancer Res Treat. 2021. PMID: 33728524
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Ciruelos E, Vidal M, Martínez de Dueñas E, Martínez-Jáñez N, Fernández Y, García-Sáenz JA, Murillo L, Carabantes F, Beliera A, Fonseca R, Gavilá J. Ciruelos E, et al. Clin Transl Oncol. 2018 Jun;20(6):753-760. doi: 10.1007/s12094-017-1784-1. Epub 2017 Nov 7. Clin Transl Oncol. 2018. PMID: 29116433 Clinical Trial.
115 results